Cargando…

Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man

SUMMARY: Gynecomastia is a symptom with a potential high disease burden. It has a variety of underlying causes, such as malignant, drug-related or hormonal. The presence of gynecomastia can be explained in thyrotoxicosis due to a concomitant disbalance of sex hormones. Interestingly, it rarely is th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadnia, N, Simsek, S, Stam, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115411/
https://www.ncbi.nlm.nih.gov/pubmed/33880994
http://dx.doi.org/10.1530/EDM-20-0181
_version_ 1783691218407915520
author Mohammadnia, N
Simsek, S
Stam, F
author_facet Mohammadnia, N
Simsek, S
Stam, F
author_sort Mohammadnia, N
collection PubMed
description SUMMARY: Gynecomastia is a symptom with a potential high disease burden. It has a variety of underlying causes, such as malignant, drug-related or hormonal. The presence of gynecomastia can be explained in thyrotoxicosis due to a concomitant disbalance of sex hormones. Interestingly, it rarely is the presenting symptom of Graves’ disease. A 49-year-old man presented to our outpatient clinic with right-sided gynecomastia. After thorough history taking, more symptoms of thyrotoxicosis were present. Treatment was started with thiamazole and later levothyroxine. Three months after this treatment the gynecomastia and other symptoms resolved completely. A disbalance of sex hormones due to an increased expression of the protein sex hormone-binding globulin (SHBG) caused by thyrotoxicosis could result in gynecomastia. In vitro and in vivo research in mice suggest that the pathophysiology of thyrotoxicosis-associated gynecomastia is due to upregulation of hepatocyte nuclear factor-4α (HNF4A) in liver cells. Subsequent increase of SHBG results in a decrease of free testosterone levels. LEARNING POINTS: Gynecomastia is a common finding (up to almost 40%) on physical examination in patients with hyperthyroidism. In gynecomastia, thyroid function tests should be examined on initial presentation because of the relative simple treatment. The pathophysiology of thyrotoxicosis-associated gynecomastia is well understood by a sex-hormonal disbalance due to an increased expression of SHBG. Due to the well explainable pathophysiology, reduction of symptoms can be expected after treatment. The underlying mechanism of an increased expression of SHBG is not well understood. However, in vitro and in vivo research in mice suggests that thyrotoxicosis causes an increased expression of HNF4A in liver cells. Thus, upregulating the expression of SHBG. Interestingly, HNF4A is suspected to play an important role in MODY. Future research will clarify the importance of this gene and might open up new insights for therapy.
format Online
Article
Text
id pubmed-8115411
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-81154112021-05-17 Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man Mohammadnia, N Simsek, S Stam, F Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy SUMMARY: Gynecomastia is a symptom with a potential high disease burden. It has a variety of underlying causes, such as malignant, drug-related or hormonal. The presence of gynecomastia can be explained in thyrotoxicosis due to a concomitant disbalance of sex hormones. Interestingly, it rarely is the presenting symptom of Graves’ disease. A 49-year-old man presented to our outpatient clinic with right-sided gynecomastia. After thorough history taking, more symptoms of thyrotoxicosis were present. Treatment was started with thiamazole and later levothyroxine. Three months after this treatment the gynecomastia and other symptoms resolved completely. A disbalance of sex hormones due to an increased expression of the protein sex hormone-binding globulin (SHBG) caused by thyrotoxicosis could result in gynecomastia. In vitro and in vivo research in mice suggest that the pathophysiology of thyrotoxicosis-associated gynecomastia is due to upregulation of hepatocyte nuclear factor-4α (HNF4A) in liver cells. Subsequent increase of SHBG results in a decrease of free testosterone levels. LEARNING POINTS: Gynecomastia is a common finding (up to almost 40%) on physical examination in patients with hyperthyroidism. In gynecomastia, thyroid function tests should be examined on initial presentation because of the relative simple treatment. The pathophysiology of thyrotoxicosis-associated gynecomastia is well understood by a sex-hormonal disbalance due to an increased expression of SHBG. Due to the well explainable pathophysiology, reduction of symptoms can be expected after treatment. The underlying mechanism of an increased expression of SHBG is not well understood. However, in vitro and in vivo research in mice suggests that thyrotoxicosis causes an increased expression of HNF4A in liver cells. Thus, upregulating the expression of SHBG. Interestingly, HNF4A is suspected to play an important role in MODY. Future research will clarify the importance of this gene and might open up new insights for therapy. Bioscientifica Ltd 2021-03-29 /pmc/articles/PMC8115411/ /pubmed/33880994 http://dx.doi.org/10.1530/EDM-20-0181 Text en © 2021 The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Insight into Disease Pathogenesis or Mechanism of Therapy
Mohammadnia, N
Simsek, S
Stam, F
Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title_full Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title_fullStr Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title_full_unstemmed Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title_short Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man
title_sort gynecomastia as a presenting symptom of graves’ disease in a 49-year-old man
topic Insight into Disease Pathogenesis or Mechanism of Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115411/
https://www.ncbi.nlm.nih.gov/pubmed/33880994
http://dx.doi.org/10.1530/EDM-20-0181
work_keys_str_mv AT mohammadnian gynecomastiaasapresentingsymptomofgravesdiseaseina49yearoldman
AT simseks gynecomastiaasapresentingsymptomofgravesdiseaseina49yearoldman
AT stamf gynecomastiaasapresentingsymptomofgravesdiseaseina49yearoldman